Compare CHD & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHD | INCY |
|---|---|---|
| Founded | 1846 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.8B | 17.0B |
| IPO Year | N/A | 1993 |
| Metric | CHD | INCY |
|---|---|---|
| Price | $92.05 | $102.63 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 21 |
| Target Price | ★ $100.39 | $96.79 |
| AVG Volume (30 Days) | ★ 2.1M | 2.1M |
| Earning Date | 01-30-2026 | 02-09-2026 |
| Dividend Yield | ★ 1.30% | N/A |
| EPS Growth | 42.14 | ★ 3878.02 |
| EPS | 3.17 | ★ 5.90 |
| Revenue | ★ $6,141,000,000.00 | $4,813,105,000.00 |
| Revenue This Year | $2.50 | $19.59 |
| Revenue Next Year | $3.34 | $10.80 |
| P/E Ratio | $28.59 | ★ $17.99 |
| Revenue Growth | 1.45 | ★ 18.09 |
| 52 Week Low | $81.33 | $53.56 |
| 52 Week High | $116.46 | $112.29 |
| Indicator | CHD | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 71.47 | 49.58 |
| Support Level | $83.52 | $102.68 |
| Resistance Level | $86.49 | $108.58 |
| Average True Range (ATR) | 1.93 | 3.55 |
| MACD | 0.78 | -0.03 |
| Stochastic Oscillator | 94.91 | 32.54 |
Church & Dwight is the leading global producer of baking soda. Its portfolio extends beyond its legacy category to include laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its brands also include Batiste, OxiClean, Vitafusion, Hero, and TheraBreath, which, together with Arm & Hammer, account for around 70% of its annual sales and profits. Most recently, the firm added Touchland and its hand sanitizer business to its fold. Even as it works to expand its product reach, Church & Dwight still derives around 80% of its sales from its home market in the US.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.